A comparison efficacy and safety study between 3 DOAC agents (rivaroxaban, dabigatran and apixaban)
Latest Information Update: 12 Apr 2021
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2021 New trial record